https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Targeting Mitophagy in Alzheimer's Disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42660 Wed 31 Aug 2022 13:09:31 AEST ]]> Depression and thoughts of self-harm and suicide among people living with dementia: results of a cross-sectional survey https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53917 Wed 28 Feb 2024 15:39:13 AEDT ]]> Neurovascular coupling mechanisms in health and neurovascular uncoupling in Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52020 Wed 27 Sep 2023 09:54:11 AEST ]]> Protective mechanism of testosterone on cognitive impairment in a rat model of Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45031 Wed 26 Oct 2022 10:52:42 AEDT ]]> JDoe: Alzheimer's portraits series https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10323 Wed 24 Jul 2013 22:27:13 AEST ]]> Optimising diagnosis and post-diagnostic support for people living with dementia: geriatricians’ views https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51144 Wed 23 Aug 2023 12:29:49 AEST ]]> The relationship between the apolipoprotein E e4 allele and hippocampal MRI volume in community dwelling individuals with mild Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28680 Diagnostic and Statistical Manual of Mental Disorders criteria for probable AD were recruited. We examined the relationship between ApoE e4 allele load and hippocampal atrophy on MRI volumes. Results: There was no association between the ApoE e4 load and hippocampal volume in this cohort. Conclusion: This study suggests that the presence of one or more ApoE e4 alleles cannot be used to estimate pathological disease load in early AD.]]> Wed 11 Apr 2018 16:08:07 AEST ]]> Identification of conversion from mild cognitive impairment to Alzheimer's Disease using multivariate predictors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12729 Wed 11 Apr 2018 15:05:34 AEST ]]> Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4456 Wed 11 Apr 2018 14:49:36 AEST ]]> Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease meuroimaging initiative (ADNI) plasma proteome dataset https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15120 Wed 11 Apr 2018 14:37:46 AEST ]]> An olfactory 'stress test' may detect preclinical Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15148 Wed 11 Apr 2018 13:22:28 AEST ]]> Protein phosphatase 2A dysfunction in Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21291 in vivo and in AD. Disruption of PP2A/Bα-Tau protein interactions likely contribute to Tau deregulation in AD. Significantly, alterations in one-carbon metabolism that impair PP2A methylation are associated with increased risk for sporadic AD, and enhanced AD-like pathology in animal models. Experimental studies have linked deregulation of PP2A methylation with down-regulation of PP2A/Bα, enhanced phosphorylation of Tau and amyloid precursor protein, Tau mislocalization, microtubule destabilization and neuritic defects. While it remains unclear what are the primary events that underlie "PP2A" dysfunction in AD, deregulation of PP2A enzymes definitely affects key players in the pathogenic process. As such, there is growing interest in developing PP2A-centric therapies for AD, but this may be a daunting task without a better understanding of the regulation and function of specific PP2A enzymes.]]> Wed 11 Apr 2018 12:53:23 AEST ]]> Cortical gyrification and sulcal spans in early stage Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15100 Wed 11 Apr 2018 11:36:23 AEST ]]> Alterations in erythrocyte fatty acid composition in preclinical Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30612 18F-Florbetaben, was employed to categorise participants as low NAL (standard uptake value ratio; SUVR < 1.35, N = 65) and high NAL or preclinical AD (SUVR ≥ 1.35, N = 35) wherein, linear models were employed to compare FA compositions between the two groups. Increased arachidonic acid (AA, p < 0.05) and decreased docosapentaenoic acid (DPA, p < 0.05) were observed in high NAL. To differentiate low from high NAL, the area under the curve (AUC) generated from a ‘base model’ comprising age, gender, APOEε4 and education (AUC = 0.794) was outperformed by base model + AA:DPA (AUC = 0.836). Our findings suggest that specific alterations in erythrocyte FA composition occur very early in the disease pathogenic trajectory, prior to cognitive impairment. As erythrocyte FA levels are reflective of tissue FA, these alterations may provide insight into the pathogenic mechanism(s) of the disease and may highlight potential early diagnostic markers and therapeutic targets.]]> Wed 11 Apr 2018 11:27:55 AEST ]]> PP2A methylation controls sensitivity and resistance to ß-amyloid-induced cognitive and electrophysiological impairments https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30261 Wed 11 Apr 2018 10:01:07 AEST ]]> Alzheimer’s disease detection using deep learning based on multimodal neuroimaging https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48984 Wed 06 Mar 2024 15:25:27 AEDT ]]> Deep assessment: a novel framework for improving the care of people with very advanced Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25973 Wed 04 Sep 2019 10:40:09 AEST ]]> Convolutional neural networks for Alzheimer's disease detection on MRI images https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45686 Wed 02 Nov 2022 16:20:05 AEDT ]]> State-switching and high-order spatiotemporal organization of dynamic functional connectivity are disrupted by Alzheimer’s disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54502 Tue 27 Feb 2024 15:19:03 AEDT ]]> Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51125 Tue 22 Aug 2023 15:51:11 AEST ]]> The protective mechanism underlying phenylethanoid glycosides (PHG) actions on synaptic plasticity in rat Alzheimer's disease model induced by beta amyloid 1-42 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36237 Tue 17 Mar 2020 12:25:30 AEDT ]]> Bacterial Infection Increases the Risk of Alzheimer's Disease: An Evidence-Based Assessment https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43171 Tue 13 Sep 2022 16:03:39 AEST ]]> Tackling Dementia Together via The Australian Dementia Network (ADNeT): A Summary of Initiatives, Progress and Plans https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54222 Tue 13 Feb 2024 12:11:44 AEDT ]]> Risk, worry and motivation: How is public knowledge of dementia shaped? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47035 Tue 13 Dec 2022 14:15:25 AEDT ]]> The protective underlying mechanisms of Schisandrin on SH-SY5Y cell model of Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44238 1-42) peptide 10 μmol/L was used to induce in vitro AD model in SH-SY5Y. Exposure to Aβ1-42 significantly reduced cell viability. Treatment with Schisandrin to Aβ1-42 exposed cells increased cell viability compared to amyloid peptide; however only the 10 μmol/L Schisandrin concentration was effective in restoring cell viability to control. Western blot analysis demonstrated that Aβ1-42 produced a significant decrease in p-Akt protein expression levels accompanied by marked elevation in p-tau and p-GSK-3β protein expression levels. Addition of 10 μmol/L Schisandrin to amyloid-treated SH-SY5Y cells was found to significantly increase protein expression levels of p-Akt associated with reduction in expression levels of p-tau and p-GSK-3β protein. Treatment with 10 μmol/L Schisandrin of SH-SY5Y cells with the p-Akt inhibitor LY294002 demonstrated that the herbal-induced rise in p-Akt protein expression was diminished by this inhibitor indicating that signal transduction occurred in the observed cellular effects. Evidence indicates that Schisandrin inhibition of Aβ1-42 -mediated cellular damage in AD neurons may involve activation of the PI3K/Akt signaling pathway where up-regulation of p-Akt activity consequently leads downstream to decreased activity of p-GSK-3β phosphorylation accompanied by reduced tau protein. Consequently, restoration of neuronal cell viability was noted. Our findings suggest that the use of Schisandrin may be considered beneficial as a therapeutic agent in AD.]]> Tue 11 Oct 2022 11:46:31 AEDT ]]> Transfer learning for Alzheimer's disease detection on MRI images https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45976 Tue 08 Nov 2022 14:19:07 AEDT ]]> Amyloid induced hyperexcitability in default mode network drives medial temporal hyperactivity and early tau accumulation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54150 Tue 06 Feb 2024 12:05:02 AEDT ]]> Successful cognitive aging is associated with thicker anterior cingulate cortex and lower tau deposition compared to typical aging https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54142 Tue 06 Feb 2024 11:57:57 AEDT ]]> The Effect of Genetic Predisposition to Alzheimer's Disease and Related Traits on Recruitment Bias in a Study of Cognitive Aging https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53491 Thu 30 Nov 2023 15:43:58 AEDT ]]> A novel feature selection approach for data integration analysis: applications to transcriptomics study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24585 Thu 29 Nov 2018 10:14:05 AEDT ]]> Beyond the obvious: smoking and respiratory infection implications on Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38949 Thu 17 Mar 2022 08:49:09 AEDT ]]> The role of protein phosphatase 2A in Alzheimer’s disease pathogenesis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36011 Thu 17 Jun 2021 16:06:18 AEST ]]> Methylenetetrahydrofolate Reductase Deficiency Deregulates Regional Brain Amyloid-β Protein Precursor Expression and Phosphorylation Levels https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43277 Thu 15 Sep 2022 12:09:32 AEST ]]> Asymmetric dimethylarginine: a possible link between vascular disease and dementia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23647 Thu 13 Oct 2016 11:33:45 AEDT ]]> Atlas-based assessment and diagnosis of Alzheimer's Disease from neuroimages https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6891 Thu 11 Jul 2019 12:22:46 AEST ]]> Atlas-based assessment and diagnosis of Alzheimer's Disease from neuroimages https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6892 Thu 11 Jul 2019 11:48:10 AEST ]]> The Catastrophe of Intracerebral Hemorrhage Drives the Capillary-Hemorrhage Dementias, Including Alzheimer's Disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55046 Thu 04 Apr 2024 13:58:38 AEDT ]]> The rise of pericytes in neurovascular research https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42682 Thu 01 Sep 2022 08:45:21 AEST ]]> In vivo neuropathology of cortical changes in elderly persons with schizophrenia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8132 Sat 24 Mar 2018 08:40:03 AEDT ]]> Mapping the effect of APOE ε4 on gray matter loss in Alzheimer's disease in vivo https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8131 .05, t-test). Diffuse cortical atrophy was detected for both ε4+ (p = .0001, permutation test) and ε4− patients (p = .0001, permutation test) relative to controls, and overall gray matter loss was about 15% in each patients group. Differences in gray matter loss between carriers and non-carriers mapped to the temporal cortex and right occipital pole (20% greater loss in carriers) and to the posterior cingulate, left orbitofrontal and dorsal fronto-parietal cortex (5–15% greater loss in non-carriers). APOE effect in AD was not significant (p > .74, ANOVA), but a significant APOE by region (temporal vs fronto-parietal cortex) interaction was detected (p = .002, ANOVA), in both early and late-onset patients (p < .05, ANOVA). We conclude that the ε4 allele modulates disease phenotype in AD, being associated with a pattern of differential temporal and fronto-parietal vulnerability.]]> Sat 24 Mar 2018 08:40:03 AEDT ]]> How to use an article about genetic association. B: are the results of the study valid? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7490 Sat 24 Mar 2018 08:37:45 AEDT ]]> How to use an article about genetic association. C: what are the results and will they help me in caring for my patients? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7492 Sat 24 Mar 2018 08:37:45 AEDT ]]> Insoluble α-synuclein in Alzheimer's disease without Lewy body formation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1370 Sat 24 Mar 2018 08:28:21 AEDT ]]> A cross-sectional community study of serum iron measures and cognitive status in older adults https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10312 0.05). In participants without dementia (n=749), neither serum ferritin in 1994/5 or 2003/4 nor change in serum ferritin between these times was related to total CAMCOG or executive function scores, with or without adjustment for gender, age, National Adult reading test, or stroke history (all p> 0.05). No relationships were observed between ferritin and cognition for participants with possible or probable dementia (n=51). All participants identified as HFE C282Y homozygous or with serum ferritin >1,000 ng/ml had normal CAMCOG scores. We conclude abnormal body iron stores (low or high) are unlikely to have clinically significant effects on cognition or dementia risk in community-dwelling older people.]]> Sat 24 Mar 2018 08:12:22 AEDT ]]> The in vivo topography of cortical changes in healthy aging and prodromal Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19040 Sat 24 Mar 2018 08:05:18 AEDT ]]> Dementia 14 essentials of assessment and care planning https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18298 Sat 24 Mar 2018 08:04:27 AEDT ]]> The role of olfactory challenge tests in incipient dementia and clinical trial design https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18865 Sat 24 Mar 2018 08:03:15 AEDT ]]> Combinatorial optimization models for finding genetic signatures from gene expression datasets https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6628 Sat 24 Mar 2018 07:46:19 AEDT ]]> Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27391 Sat 24 Mar 2018 07:34:10 AEDT ]]> Protective effects of testosterone on cognitive dysfunction in Alzheimer's disease model rats induced by oligomeric beta amyloid peptide 1-42 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25303 Sat 24 Mar 2018 07:30:19 AEDT ]]> Matrix metalloproteinases and related proteins in Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3895 Sat 24 Mar 2018 07:22:41 AEDT ]]> Using set of experience knowledge structure to extend a rule set of clinical decision support system for Alzheimer's disease diagnosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22307 Sat 24 Mar 2018 07:11:05 AEDT ]]> Assessment of evidence for or against contributions of Chlamydia pneumoniae infections to Alzheimer's disease etiology https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38383 Mon 29 Jan 2024 17:45:07 AEDT ]]> ConvADD: Exploring a Novel CNN Architecture for Alzheimer’s Disease Detection https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55405 Mon 27 May 2024 12:04:01 AEST ]]> The relationship of iron and amyloid: insights from a new mouse model of iron loading and amyloidosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36313 Mon 23 Aug 2021 12:41:47 AEST ]]> Mitoprotective Effects of a Synergistic Nutraceutical Combination: Basis for a Prevention Strategy Against Alzheimer’s Disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53267 Mon 20 Nov 2023 12:49:07 AEDT ]]> Methyl donor supplementation reduces phospho-Tau, Fyn and demethylated protein phosphatase 2A levels and mitigates learning and motor deficits in a mouse model of tauopathy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52534 Mon 16 Oct 2023 14:56:57 AEDT ]]> Deaths with Dementia in Indigenous and Non-Indigenous Australians: A Nationwide Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41897 2, test for interaction p < 0.0001), and among men (test for interaction p < 0.0001). When the underreporting of Indigenous status on the death certificate was taken into account the relative rate increased to 2.17, 95% CI (2.07, 2.29). Indigenous Australians were also more likely to have their dementia coded as 'unspecified' on their death certificate (Odds Ratio 1.92, 95% CI (1.66, 2.21), p<0.0001), compared to the non-Indigenous group. Conclusion: This epidemiological analysis based on population level mortality data demonstrates the higher dementia-related mortality rate for Indigenous Australians especially at younger ages.]]> Mon 15 Aug 2022 12:23:26 AEST ]]> Primary care physicians' perceived barriers to optimal dementia care: A systematic review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36852 Mon 13 Jul 2020 10:41:17 AEST ]]> Dementia Detection from Speech Using Machine Learning and Deep Learning Architectures https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52320 Mon 09 Oct 2023 10:24:36 AEDT ]]> Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38563 Mon 09 May 2022 16:16:35 AEST ]]> Astrocyte remodeling in the beneficial effects of long-term voluntary exercise in Alzheimer's disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38402 Mon 06 Sep 2021 16:41:33 AEST ]]> Alzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55259 Mon 06 May 2024 12:35:54 AEST ]]> Perceptions of people living with dementia regarding patient-centred aspects of their care and caregiver support https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50568 Fri 28 Jul 2023 11:34:42 AEST ]]> Regional changes with global brain hypometabolism indicates a physiological triage phenomenon and can explain shared pathophysiological events in Alzheimer's & small vessel diseases and delirium. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48100 Fri 24 Feb 2023 15:31:10 AEDT ]]> Vascular senescence and leak are features of the early breakdown of the blood–brain barrier in Alzheimer’s disease models https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53851 Fri 19 Jan 2024 10:25:09 AEDT ]]> Tuberous Sclerosis Complex‐1 (TSC1) contributes to selective neuronal vulnerability in Alzheimer’s Disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53129 Fri 17 Nov 2023 12:17:13 AEDT ]]> Deep learning to detect Alzheimer's disease from neuroimaging: a systematic literature review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39085 Fri 06 May 2022 15:49:33 AEST ]]> Exploring causal architecture of schizophrenia and Alzheimer's disease to identify new drug targets https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55915 Fri 05 Jul 2024 10:24:11 AEST ]]> Prevalence and type of unmet needs experienced by carers of people living with dementia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51368 Fri 01 Sep 2023 13:44:49 AEST ]]>